
News|Articles|December 8, 2010
ASH 2010 Homepage Header
Advertisement
Oncology NEWS International reports on critical information from the American Society of Hematology's 52nd annual meeting.
- Rituximab instead of ‘watch and wait’ policy in asymptomatic follicular lymphoma causes controversy
- Ofatumumab generates high response rates in refractory CLL
- Industry update: Early-stage trials establish pathways for new treatment agents
- More Coverage from ASH 2010
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
3
SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC
4
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
5


















































































